In a nutshell The review aimed to develop recommendations for stopping tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia CML. Some background Tyrosine kinase inhibitors (TKI) are a type of targeted therapy. TKIs have improved the survival outcomes for patients with chronic myeloid...
Read More
In a nutshell This study aimed to investigate long-term treatment-free remission (TFR) for patients with chronic-phase (CP) chronic myeloid leukemia (CML) who were treated with nilotinib (Tasigna) as a second-line treatment. This study concluded that TFR is safe and durable in these patients. Some background The...
Read More
In a nutshell This study provided an updated 5-year assessment of treatment-free remission (TFR) after frontline nilotinib (Tasigna) treatment in patients with chronic-phase (CP) chronic myeloid leukemia (CML). The data showed sustained, long-term high TFR rates with effectiveness and safety in these patients. Some background Long-term treatments...
Read More
In a nutshell This study aimed to investigate the outcomes and side effects of ibrutinib in patients with chronic lymphocytic leukemia in the real-world setting. This study concluded that the outcomes for these patients in the real-world setting were similar to clinical trials but the rate of side...
Read More
In a nutshell This review aimed to discuss the toxicities of ibrutinib (Imbruvica) treatment and how to manage them. This review concluded that patients should be regularly monitored for toxicities and actively treated to reduce side effects and avoid disruption to treatment. Some background Ibrutinib is a...
Read MoreIn a nutshell The study evaluated the combined effects of imatinib (IM; Gleevec) and hydroxychloroquine (HCQ; Plaquenil) in patients with chronic-phase chronic myeloid leukemia (CP-CML) and residual leukemic stem cells. The authors found that this combination safely and moderately improved treatment outcomes in such patients compared to IM alone. Some...
Read MoreIn a nutshell This study aimed to investigate the long-term safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study concluded that ibrutinib was safe and effective in the long-term in this group. Some background Ibrutinib (Imbruvica) is a...
Read More
In a nutshell This study aimed to investigate the outcomes of stem cell transplant in patients with blast crisis chronic myeloid leukemia who were pre-treated with tyrosine kinase inhibitors. This study concluded that the survival of these patients was strongly dependent on pretransplant remission status. Some background...
Read More
In a nutshell This study aimed to investigate the frequency of BCR-ABL kinase domain mutation detection and its prognostic significance in patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs). This study concluded that early mutation detection and use of 2nd and...
Read More
In a nutshell This study aimed to investigate the ending of imatinib treatment in patients with chronic-phase chronic myeloid leukemia who had at least 2 years of deep molecular response from imatinib first line treatment. This study concluded that the duration of treatment and residual...
Read More
In a nutshell This study aimed to investigate the risk of cardiovascular (heart and blood vessel) side effects in patients with chronic myeloid leukemia who were treated with tyrosine kinase inhibitors. This study concluded that these side effects were more frequent in this group of patients. Some background Cardiovascular events (CVE) have been...
Read MoreIn a nutshell This study aimed to investigate the symptom burden on patients with chronic phase chronic myeloid leukemia (CP-CML) who were treated with second or third generation tyrosine kinase inhibitors. This study concluded that the side effects of this treatment may affect the quality of life for these patients. Some background Chronic myeloid...
Read More
